Meet Our Immunology Leadership Team
David Lee leads the Immunology Therapeutic Area (TA) at Janssen Research & Development where he is responsible for generating and implementing global TA strategies to effectively discover and advance Janssen candidate therapeutics through registration. Within Janssen R&D, the Immunology TA focuses on immune-mediated diseases and has a proven track record in providing treatments for patients with rheumatic, gastrointestinal and dermatologic diseases. Marketed products include REMICADE®, SIMPONI®, SIMPONI® ARIA, STELARA® and TREMFYA®. The Janssen Immunology portfolio also includes Discovery and Early Development programs that build on its world-class expertise in immunology where key pathways can be leveraged to treat the fundamental underlying causes of immune-mediated diseases.
Prior to joining Janssen, David served as Global Head, Immunology, Inflammation and Infectious Disease Discovery and Translation Area for Roche. Prior to his role at Roche, he was Global Head of Autoimmunity, Dermatology, and Transplant Translational Medicine at the Novartis Institutes for BioMedical Research (NIBR). David was a member of the academic faculty at Brigham & Women’s Hospital/Harvard Medical school for 10 years. He earned his medical and graduate degrees from Duke University School of Medicine and served his post-graduate medical residency and rheumatology fellowship at Brigham & Women’s Hospital, Harvard Medical School.
David M. Lee, M.D., Ph.D.
Global Therapeutic Area Head,
Janssen Research & Development
Teri Lawver is the Global Commercial Strategy Leader, Global Vice President, for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. In this role, Teri has end-to-end responsibility for the Janssen Immunology portfolio and pipeline.
Teri has more than 20 years of global healthcare and business leadership experience spanning three continents, three healthcare sectors, and dozens of disease areas. She has a proven track record in building new businesses, delivering sustainable, innovation-based growth, and developing high-performance teams.
Teri joined Johnson & Johnson at Centocor in 2002. During her 5 years at Centocor she advanced through leadership positions in Marketing, Sales, and Strategic Accounts Management, and was responsible for launching and leading the first Remicade Gastroenterology Marketing and Sales Teams.
From 2007 through 2013 Teri progressed through General Management positions in our Medical Device Sector, and in 2011 was appointed President of Johnson & Johnson Medical Device Companies in Canada. In 2013 Teri was appointed Global Commercial Strategy Leader, Global Vice President for the Janssen Cardiovascular & Metabolism Therapeutic Area.
Before joining Johnson & Johnson, Teri was an Associate Principal with McKinsey & Company in the Firm’s New Jersey, Atlanta, and Sao Paolo, Brazil offices and was a leader in the Firm’s Global Healthcare Practice. She began her career as a Derivatives Analyst with Bloomberg Financial Markets, LLP.
She holds a Bachelor of Science degree, summa cum laude, from Georgetown University, and a Master of Business Administration from Duke University.
Active with community and philanthropic causes, Teri serves on the Advisory Council of the NetsforLife® Partnership for Malaria Prevention in Africa, and on the Advancement Committee for Episcopal Relief & Development, where she champions promoting health and fighting disease among the world’s most under-served populations. She was recently named to the NJBiz “Best 50 Women in Business” list for 2016.
Teri L. Lawver
Global Commercial Strategy Leader, Global Vice President, Immunology Janssen Research & Development
With nearly 25 years of experience in the pharmaceutical and biotechnology industry, Ian Anderson, Ph.D. leads immunology discovery and collaboration efforts globally in partnership with the Johnson & Johnson Innovation Centers. In this role, Ian applies the highest level of scientific expertise and insights to identify the best opportunities for value-generating collaborations and, in developing an industry-leading portfolio of investments, cultivates a strong scientific reputation and network of experts around the world.
Ian Anderson, Ph.D.
Vice President, Immunology Discovery & Scientific Innovation, Janssen Research & Development
Mark Cunningham is responsible for strategic and operational activities across the Immunology Therapeutic Area. This includes optimizing internal business practices, managing the execution of external science and enabling decisions at the portfolio level. Since joining the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor Research & Development in 2001, Mark has leveraged years of experience in scientific research, business planning and project management to drive excellence in drug discovery and development by embracing technology and supporting collaboration without boundaries.
Head, Strategy & Business Planning, Immunology, Janssen Research & Development
As Head of Immunology Development, Newman Yeilding, M.D. provides scientific and management leadership of development initiatives and investments globally, directing and overseeing all programs supporting new molecular entities within the rheumatoid arthritis, inflammatory bowel disease and psoriasis disease area portfolios, and life cycle indications for the industry-leading Janssen immunology portfolio. Newman joined the Janssen Pharmaceutical Companies of Johnson & Johnson through Centocor in 2002, and was instrumental in the development and approval of one of the company’s leading biologics, which he has continued to oversee through new indications in dermatology and gastroenterology.
Newman Yeilding, M.D.
Head of Development, Immunology, Janssen Research & Development
As Disease Area Leader for Rheumatology, George Vratsanos is responsible for leading a cross-functional team of experts to outline prioritized scientific and business strategies with the goal of maintaining industry leadership in rheumatology and paving the way for the newly-defined focus on lupus.
George joined Janssen Research & Development in 2016 as Vice President, Immunology Translational Science and Medicine (ITSM) where he played an integral role in steering the newly created team designed to elevate and better guide the scientific, translational and development aspects of immunology drug development at Janssen. He has also served as a member of the Immunology Management Board (IMB) and the Immunology Senior Leadership Team (SLT).
George Vratsanos, M.D.
Disease Area Leader, Rheumatology, Janssen Research & Development
Pearl Pugh, Disease Area Commercial Leader, is responsible for developing and executing the end-to-end strategy for the Rheumatology and Psoriasis Disease Area Strongholds. This involves leading a team of global commercial strategy and analytics professionals to develop deep insights to inform differentiated development and commercial strategies and approaches.
Pearl also provides leadership to global commercial teams to ensure effective partnerships with cross-functional and regional stakeholders to ensure worldwide launch readiness for new products and line extensions, and to maximize current in-market assets worldwide.
Disease Area Commercial Leader, Rheumatology & Dermatology,
Janssen Global Services
Scott Plevy, M.D. is a distinguished, board-certified gastroenterologist who comes to Janssen after a successful career in academia. He has been the lead investigator on multiple early-phase clinical trials and has performed translational research to advance the understanding of novel immunologic interventions. In addition, Scott has contributed to more than 80 peer-reviewed publications concentrating on inflammatory bowel disease (IBD). As IBD Disease Area Stronghold Leader, Scott is responsible for outlining strategies to advance new paradigms for treatment and intervention, collaborating with several internal groups to identify priority targets for drug discovery and development that will enhance the current IBD portfolio.
Scott Plevy, M.D.
Disease Area Stronghold Leader, Inflammatory Bowel Disease, Janssen Research & Development
Albert Lee is Disease Area Commercial Leaders, Gastroenterology. He has spent more than 20 years at Johnson & Johnson, in roles of increasingly responsibility including sales, marketing and general management across different geographies and franchises.
Prior to his current role, he led the integration of the DepuySynthes across six countries (Thailand, Malaysia, Singapore, Vietnam, Indonesia and Philippines) as the General Manager of South East Asia. From 2010 to 2012, he was the Association of Southeast Asian Nations (ASEAN) Franchise Director for Depuy and Country Director of Singapore. In 2007, he was selected to participate in an International Development Program in the US and UK, before moving to Thailand, in 2008, as Franchise Director.
In recognition of his leadership and passionate involvement in the Healthcare industry, Albert was elected Chairman for Medical Technology Industry Group by Singapore Manufacturing Federation (SMF MTIG) since 2014. Albert is also on the Board of Directors of Singapore Association of Pharmaceuticals Industries (SAPI) and on the Alumni Advisory Board of Nanyang Technological University Business School. He is also a Member of Medical Devices Industry Policy Review Working Group, Health Sciences Authority (HSA).
Albert holds a Bachelor of Business degree in Marketing from Nanyang Technological University in Singapore and an Master in Business Administration from Duke University in Durham, North Carolina.
Disease Area Commercial Leader,
Janssen Global Services
Mark Curran, Ph.D. is responsible for delivering the biomarker strategy, integrated patient solutions, big data analysis and development of companion diagnostics for the Immunology Therapeutic Area. His team works to incorporate emerging science and human genetics into new programs with the goal of creating personalized treatment approaches that are predictive of response. Mark’s deep scientific expertise, entrepreneurial passion and commitment to people development continues to strengthen Janssen Immunology leadership in this evolving area of focus.
Mark Curran, Ph.D.
Vice President, Systems Pharmacology & Biomarkers, Janssen Research & Development
As the driver of immunology-focused collaborations out of Johnson & Johnson Innovation, Boston, Michael Elliott, M.B.B.S., Ph.D., F.R.A.C.P. taps into a long-established network of relationships in the Boston area to identify novel and exciting areas of research to pursue. In this role, Michael applies the highest-level scientific expertise and insights to identify the best opportunities for value-generating collaborations, and in developing an industry-leading portfolio of investments, while cultivating a strong scientific reputation and a network of experts in the Boston and broader Northeastern United States innovation community.
Michael Elliott, M.B.B.S., Ph.D., F.R.A.C.P.
Global Head of Immunology Discovery & Scientific Innovation, Janssen Research & Development
Jackie Benson, Ph.D. leads immunology-focused collaborations out of the Johnson & Johnson Innovation Center located in California. Jackie is responsible for identifying the best external innovation opportunities and value-generating partnerships to further develop the organization’s industry-leading portfolio of Immunology investments. In this role, she works to advance the Immunology Therapeutic Area strategy while building a strong scientific reputation and network of experts in California and the broader Western United States innovation community.
Jacqueline Benson, Ph.D.
Vice President, Immunology Scientific Innovation, Johnson & Johnson Innovation, California
Biao Zheng, Ph.D., M.D. leads immunology-focused collaborations out of the Johnson & Johnson Innovation Center located in Shanghai, China. Biao is responsible for identifying the best external innovation opportunities and value-generating partnerships to further develop the organization’s industry-leading portfolio of Immunology investments. In this role, he works to advance the Immunology Therapeutic Area strategy while building a strong scientific reputation and network of experts across the Asia Pacific innovation community.
Biao Zheng, Ph.D., M.D.
Vice President, Immunology Scientific Innovation, Johnson & Johnson Innovation, Asia Pacific
Louise Jopling, Ph.D. leads immunology-focused collaborations out of the Johnson & Johnson Innovation Center located in London. Louise is responsible for identifying the best external innovation opportunities and value-generating partnerships to further develop the organization’s industry-leading portfolio of Immunology investments. In this role, she works to advance the Immunology Therapeutic Area strategy while building a strong scientific reputation and network of experts in London and the broader European innovation community.